Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 348686, 9 pages
http://dx.doi.org/10.1155/2011/348686
Research Article

Effect of Hachimijiogan against Renal Dysfunction and Involvement of Hypoxia-Inducible Factor-1α in the Remnant Kidney Model

1Department of Japanese Oriental Medicine, Graduate school of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
2Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
3Department of Kampo Diagnostics, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
4Biomedical Institute, NPO Primate Agora, Inuyama, Aichi 484-0002, Japan
5Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
6Faculty of Human Development, University of Toyama, 3190 Gofuku, Toyama 930-8555, Japan

Received 2 November 2010; Accepted 7 January 2011

Copyright © 2011 Hiroshi Oka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Lysaght, “Maintenance dialysis population dynamics: current trends and long-term implications,” Journal of the American Society of Nephrology, vol. 13, supplement 1, pp. S37–S40, 2001. View at Google Scholar
  3. G. Remuzzi and T. Bertani, “Pathophysiology of progressive nephropathies,” New England Journal of Medicine, vol. 339, no. 20, pp. 1448–1456, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. L. G. Fine, D. Bandyopadhay, and J. T. Norman, “Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia,” Kidney International, Supplement, vol. 57, no. 75, pp. S22–S26, 2000. View at Google Scholar
  5. K. U. Eckardt, C. Rosenberger, J. S. Jürgensen, and M. S. Wiesener, “Role of hypoxia in the pathogenesis of renal disease,” Blood Purification, vol. 21, no. 3, pp. 253–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Marx, “How cells endure low oxygen,” Science, vol. 303, no. 5663, pp. 1454–1456, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Ohtomo, M. Nangaku, Y. Izuhara, S. Takizawa, C. Y. Strihou, and T. Miyata, “Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model,” Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1166–1172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Masuda, A. Shimizu, T. Mori et al., “Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis,” American Journal of Pathology, vol. 159, no. 2, pp. 599–608, 2001. View at Google Scholar · View at Scopus
  9. K. Terasawa, “Kampo: Japanese-Oriental Medicine, insights from clinical cases,” K.K. Standard McIntyre, pp. 243–244, 1993. View at Google Scholar
  10. T. Nakagawa, T. Yokozawa, N. Yamabe et al., “Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats,” Journal of Pharmacy and Pharmacology, vol. 57, no. 9, pp. 1205–1212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Yamabe, T. Yokozawa, H. Y. Kim, and E. J. Cho, “Protective effect of Hachimi-jio-gan against renal failure in a subtotal nephrectomy rat model,” Journal of Pharmacy and Pharmacology, vol. 57, no. 12, pp. 1637–1644, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Manotham, T. Tanaka, M. Matsumoto et al., “Evidence of tubular hypoxia in the early phase in the remnant kidney model,” Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1277–1288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Tanaka, I. Kojima, T. Ohse et al., “Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model,” Laboratory Investigation, vol. 85, no. 10, pp. 1292–1307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Kumada, K. Tsuneyama, H. Hatta, S. Ishizawa, and Y. Takano, “Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital,” Modern Pathology, vol. 17, no. 9, pp. 1141–1149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Nangaku and K. U. Eckardt, “Hypoxia and the HIF system in kidney disease,” Journal of Molecular Medicine, vol. 85, no. 12, pp. 1325–1330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. Wenger, D. P. Stiehl, and G. Camenisch, “Integration of oxygen signaling at the consensus HRE,” Science's STKE, vol. 2005, no. 306, p. re12, 2005. View at Google Scholar · View at Scopus
  17. P. Katavetin, T. Miyata, R. Inagi et al., “High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1405–1413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Katavetin, R. Inagi, T. Miyata et al., “Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway,” Biochemical and Biophysical Research Communications, vol. 367, no. 2, pp. 305–310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. H. Hostetter, J. L. Olson, H. G. Rennke, M. A. Venkatachalam, and B. M. Brenner, “Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation,” Journal of the American Society of Nephrology, vol. 12, no. 6, pp. 1315–1325, 2001. View at Google Scholar · View at Scopus
  20. Y. R. Song, S. J. You, Y. M. Lee et al., “Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 77–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Hirawa, Y. Uehara, Y. Kawabata et al., “Hachimi-jio-gan extract protects the kidney from hypertensive injury in dahl salt-sensitive rat,” American Journal of Chinese Medicine, vol. 24, no. 3-4, pp. 241–254, 1996. View at Google Scholar · View at Scopus
  22. T. Yokozawa, N. Yamabe, E. J. Cho, T. Nakagawa, and S. Oowada, “A study on the effects to diabetic nephropathy of hachimi-jio-gan in rats,” Nephron Experimental Nephrology, vol. 97, no. 2, pp. e38–e48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Yamabe, K. S. Kang, E. Goto, T. Tanaka, and T. Yokozawa, “Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats,” Biological and Pharmaceutical Bulletin, vol. 30, no. 3, pp. 520–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ueshima, S. Yasuno, K. Oba et al., “Impact of left ventricular hypertrophy on the time-course of renal function in hypertensive patients: a subanalysis of the CASE-J trial,” Circulation Journal, vol. 74, no. 10, pp. 2132–2138, 2010. View at Publisher · View at Google Scholar
  25. P. Morsing, “Candesartan: a new-generation angiotensin II AT receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection,” Journal of the American Society of Nephrology, vol. 10, supplement 11, pp. S248–S254, 1999. View at Google Scholar · View at Scopus
  26. H. Rincon-Choles, B. S. Kasinath, Y. Gorin, and H. E. Abboud, “Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy,” Kidney International, Supplement, vol. 62, no. 82, pp. S8–S11, 2002. View at Google Scholar · View at Scopus
  27. E. Dounousi, E. Papavasiliou, A. Makedou et al., “Oxidative stress is progressively enhanced with advancing stages of CKD,” American Journal of Kidney Diseases, vol. 48, no. 5, pp. 752–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Dou, N. Jourde-Chiche, V. Faure et al., “The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 5, no. 6, pp. 1302–1308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Sela, R. Shurtz-Swirski, M. Cohen-Mazor et al., “Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2431–2438, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. J. Welch, J. Blau, H. Xie, T. Chabrashvili, and C. S. Wilcox, “Angiotensin-induced defects in renal oxygenation: role of oxidative stress,” American Journal of Physiology, vol. 288, no. 1, pp. H22–H28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Rosenberger, M. Khamaisi, Z. Abassi et al., “Adaptation to hypoxia in the diabetic rat kidney,” Kidney International, vol. 73, no. 1, pp. 34–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. T. W. Kurtz and M. Pravenec, “Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system,” Journal of Hypertension, vol. 22, no. 12, pp. 2253–2261, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. D. G. Nagle and Y. D. Zhou, “Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1),” Current Pharmaceutical Design, vol. 12, no. 21, pp. 2673–2688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. W. J. Wilson and L. Poellinger, “The dietary flavonoid quercetin modulates HIF-1α activity in endothelial cells,” Biochemical and Biophysical Research Communications, vol. 293, no. 1, pp. 446–450, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Thomas and M. H. Kim, “Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells,” Biochemical and Biophysical Research Communications, vol. 334, no. 2, pp. 543–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Zhang, X. Tang, Q. Lu, Z. Zhang, J. Rao, and A. D. Le, “Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1227–1238, 2006. View at Publisher · View at Google Scholar · View at Scopus